Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

P. Gopalakrishna, F. Cappuzzo, B. Coudert, T. Ciuleanu, K. Park, Y.- L. Wu, G. Giaccone, W. Brugger
  • Annals of Oncology, May 2011, Oxford University Press (OUP)
  • DOI: 10.1093/annonc/mdr125

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Federico Cappuzzo